Evotec Receives Milestone Payment for Initiating Ph II Trials of Persistent Cough Drug

Evotec AG (OTC PINK: EVTCY) (FSE: EVTA) (XETRA: EVT) announced on 2/28/19 that a promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough. As a result of the trial initiation, Evotec received a payment of $3.4 million.